Keywords: Idenix, IDX184, Hepatitis C, USA, FDA, Partial clinical hold

Idenix plunges as FDA puts clinical hold on hepatitis C drug candidate

Article | 17 August 2012

Print This

US biotech firm Idenix Pharmaceuticals (Nasdaq: IDIX) saw its shares tank 29% to $5.91 in morning trading after the company revealed that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in